1. pregnancy (or positive urine pregnancy test) or lactating. 2. more than 14 days following completion of sars-cov-2 vaccition series 3. the following pre-existing medical conditions: 1. known cirrhosis with any history of decompensation (ascites, variceal bleeding or hepatic encephalopathy) 2. known chronic kidney disease with estimated creatinine clearance \< 30 ml/minute or need for dialysis 3. uncontrolled severe psychiatric disorder - schizophrenia, bipolar disorder, depression with prior suicidality 4. uncontrolled seizures or seizure in the prior 1 month 5. any other underlying medical (cardiac, liver, renal, neurological, respiratory) or psychiatric condition that in the view of the investigator would preclude use of peginterferon lambda 4. known alcohol or drug dependence that in the opinion of the investigator would impair study participation. 5. known prior intolerance to interferon treatment. 6. enrolment in another clinical trial testing an antiviral agent or receipt of an antiviral agent for covid-19 in the past 7 days. 7. use of investigational, off-label therapy for covid-19, or unproven therapy for covid-19.

1. pregnancy (or positive urine pregnancy test) or lactating. 2. more than 14 days following completion of sars-cov-2 vaccition series 3. the following pre-existing medical conditions: 1. known cirrhosis with any history of decompensation (ascites, variceal bleeding or hepatic encephalopathy) 2. known chronic kidney disease with estimated creatinine clearance \< 30 ml/minute or need for dialysis 3. uncontrolled severe psychiatric disorder - schizophrenia, bipolar disorder, depression with prior suicidality 4. uncontrolled seizures or seizure in the prior 1 month 5. any other underlying medical (cardiac, liver, renal, neurological, respiratory) or psychiatric condition that in the view of the investigator would preclude use of peginterferon lambda 4. known alcohol or drug dependence that in the opinion of the investigator would impair study participation. 5. known prior intolerance to interferon treatment. 6. enrolment in another clinical trial testing an antiviral agent or receipt of an antiviral agent for covid-19 in the past 7 days. 7. use of investigational, off-label therapy for covid-19, or unproven therapy for covid-19.

pregnancy (or positive urine pregnancy test) or lactating. more than 14 days following completion of sars-cov-2 vaccition series the following pre-existing medical conditions: known cirrhosis with any history of decompensation (ascites, variceal bleeding or hepatic encephalopathy) known chronic kidney disease with estimated creatinine clearance < 30 ml/minute or need for dialysis uncontrolled severe psychiatric disorder - schizophrenia, bipolar disorder, depression with prior suicidality uncontrolled seizures or seizure in the prior 1 month any other underlying medical (cardiac, liver, renal, neurological, respiratory) or psychiatric condition that in the view of the investigator would preclude use of peginterferon lambda known alcohol or drug dependence that in the opinion of the investigator would impair study participation. known prior intolerance to interferon treatment. enrolment in another clinical trial testing an antiviral agent or receipt of an antiviral agent for covid-19 in the past 7 days. use of investigational, off-label therapy for covid-19, or unproven therapy for covid-19.

pregnancy (or positive urine pregnancy test) or lactating. more than 14 days following completion of sars-cov-2 vaccition series the following pre-existing medical conditions: known cirrhosis with any history of decompensation (ascites, variceal bleeding or hepatic encephalopathy) known chronic kidney disease with estimated creatinine clearance < 30 ml/minute or need for dialysis uncontrolled severe psychiatric disorder - schizophrenia, bipolar disorder, depression with prior suicidality uncontrolled seizures or seizure in the prior 1 month any other underlying medical (cardiac, liver, renal, neurological, respiratory) or psychiatric condition that in the view of the investigator would preclude use of peginterferon lambda known alcohol or drug dependence that in the opinion of the investigator would impair study participation. known prior intolerance to interferon treatment. enrolment in another clinical trial testing an antiviral agent or receipt of an antiviral agent for covid-19 in the past 7 days. use of investigational, off-label therapy for covid-19, or unproven therapy for covid-19.

1. pregnancy (or positive urine pregnancy test) or lactating. 2. more than 14 days following completion of sars-cov-2 vaccition series 3. the following pre-existing medical conditions: 1. known cirrhosis with any history of decompensation (ascites, variceal bleeding or hepatic encephalopathy) 2. known chronic kidney disease with estimated creatinine clearance < 30 ml/minute or need for dialysis 3. uncontrolled severe psychiatric disorder - schizophrenia, bipolar disorder, depression with prior suicidality 4. uncontrolled seizures or seizure in the prior 1 month 5. any other underlying medical (cardiac, liver, renal, neurological, respiratory) or psychiatric condition that in the view of the investigator would preclude use of peginterferon lambda 4. known alcohol or drug dependence that in the opinion of the investigator would impair study participation. 5. known prior intolerance to interferon treatment. 6. enrolment in another clinical trial testing an antiviral agent or receipt of an antiviral agent for covid-19 in the past 7 days. 7. use of investigational, off-label therapy for covid-19, or unproven therapy for covid-19.

1. pregnancy (or positive urine pregnancy test) or lactating. 2. more than 14 days following completion of sars-cov-2 vaccition series 3. the following pre-existing medical conditions: 1. known cirrhosis with any history of decompensation (ascites, variceal bleeding or hepatic encephalopathy) 2. known chronic kidney disease with estimated creatinine clearance < 30 ml/minute or need for dialysis 3. uncontrolled severe psychiatric disorder - schizophrenia, bipolar disorder, depression with prior suicidality 4. uncontrolled seizures or seizure in the prior 1 month 5. any other underlying medical (cardiac, liver, renal, neurological, respiratory) or psychiatric condition that in the view of the investigator would preclude use of peginterferon lambda 4. known alcohol or drug dependence that in the opinion of the investigator would impair study participation. 5. known prior intolerance to interferon treatment. 6. enrolment in another clinical trial testing an antiviral agent or receipt of an antiviral agent for covid-19 in the past 7 days. 7. use of investigational, off-label therapy for covid-19, or unproven therapy for covid-19.